-
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted...
IN THE SPOTLIGHT
-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
Aiming for a Cure: How CD74 Research Could Eliminate Drug-Resistant Lung Cancer for Good
Lung cancer remains the leading cause of cancer death worldwide. Over the past two decades, the development of targeted therapies, particularly tyrosine kinase inhibitors (TKIs)... -
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community.
Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy
Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy
Natural compounds for non-small cell lung cancer treatment: focus on the EGFR signaling pathway
Natural compounds for non-small cell lung cancer treatment: focus on the EGFR signaling pathway
Discrepancy between cystatin C-based and creatinine-based eGFR predicts all-cause mortality in a community-based population: the Takahata study
Discrepancy between cystatin C-based and creatinine-based eGFR predicts all-cause mortality in a community-based population: the Takahata study
CIRCLE-F/V: a dual-mode CRISPR-Cas13a cascade biosensor for ultrasensitive and visual detection of low-abundance EGFR mutations
CIRCLE-F/V: a dual-mode CRISPR-Cas13a cascade biosensor for ultrasensitive and visual detection of low-abundance EGFR mutations
PFS 近 5 年、肿瘤病灶基本消失：奥希替尼联合化疗一线治疗改写多发转移 EGFR 突变肺癌结局_腾讯新闻
Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System
Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System
The Possible Relationship Between Adverse Drug Reactions and Potential Drug–Drug Interactions in Patients with NSCLC Treated with EGFR Inhibitors
The Possible Relationship Between Adverse Drug Reactions and Potential Drug–Drug Interactions in Patients with NSCLC Treated with EGFR Inhibitors
Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer
Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer